Study of selinexor after transplant for high-risk leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether giving two medicines, called selinexor and melphalan, twice a week after a stem cell transplant can help prevent acute myeloid leukemia from coming back. It's for people with high-risk AML who are 55 or older and whose cancer is in remission before the transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of blood cancer called acute myeloid leukemia (AML), but not the rare subtype known as acute promyelocytic leukemia.
- You must be planning to receive or have already received a stem cell transplant (from a donor).
- You must be 55 years old or older.
- Before the transplant, your leukemia must be in complete remission, confirmed by a bone marrow test done within 3 days before starting the trial.
- You must be able to take care of yourself (a score of at least 60 on a standard performance scale) and be willing to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, selinexor and azacitidine, for people with high-risk blood cancers like acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The goal is to see if this combination can help control the disease, especially before a stem cell transplant.
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
This Phase 3 trial studies selinexor (a medicine that changes signals inside cancer cells) used together with other leukemia treatment regimens for adults whose acute myeloid leukemia (AML) has come back or did not respond to standard therapy. It may help people reach remission or control the disease better than the current approach.
This study compares two approaches for adults with high-risk acute myeloid leukemia (AML) who have had one round of chemo. One option is a stem cell transplant from a donor (using someone else's cells to rebuild your bone marrow), and the other is more chemotherapy or other treatments. The goal is to see which approach works better for people like you.
This study tests whether doctors can predict which patients with relapsed or hard-to-treat multiple myeloma will respond well to a drug called selinexor. Researchers will collect blood and bone marrow samples to identify markers that help personalize treatment decisions.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.